H.C. Wainwright lowered the firm’s price target on Cogent Biosciences (COGT) to $12 from $14 and keeps a Buy rating on the shares following the Q1 report. The firm factored in an equity raise in Q4 of this year.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences: Promising Pipeline and Market Opportunities Drive Buy Rating
- Cogent Biosciences price target lowered to $7 from $8 at Baird
- Cogent Biosciences Advances with Promising Clinical Trials
- Cogent Biosciences reports Q1 net loss $72M
- Cogent Biosciences appoints Ray Frost as SVP, Market Access
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue